Integrated genomics has identified a new AT/RT-like yet INI1-positive brain tumor subtype among primary pediatric embryonal tumors

BMC Medical Genomics

Tai-Tong Wong²  Hsei-Wei Wang¹  Meng-En Chao²  Ting-Yu Chang³  Shih-Chieh Lin⁴  Chin-Han Tsai⁷  Tsung-Han Hsieh²  Chan-Yen Tsai³  Muh-Lii Liang⁶  Chuan-Chi Shih⁷  Donald Ming-Tak Ho⁵ 

[1] Department of Education and Research, Taipei City Hospital, Taipei, Taiwan;Department of Neurosurgery Taipei Medical University Hospital, Taipei Medical University, Taipei, Taiwan;Institute of Microbiology and Immunology, National Yang-Ming University, Taipei, Taiwan;Department of Pathology and Laboratory Medicine, Taipei Veterans General Hospital, Taipei, Taiwan;School of Medicine, National Yang-Ming University, Taipei, Taiwan;Division of Pediatric Neurosurgery, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan;Department of Obstetrics and Gynecology, Hsin-Chu Mackay Memorial Hospital, Hsin Chu, Taiwan

关键词: Stem cell;    Transcriptome;    Pediatric embryonal brain tumor;    INI1;    Atypical teratoid/rhabdoid tumor;   

Others  :  1219427
DOI  :  10.1186/s12920-015-0103-3

 received in 2014-11-22, accepted in 2015-05-29,  发布年份 2015

【 摘 要 】

Background

Pediatric embryonal brain tumors (PEBTs), which encompass medulloblastoma (MB), primitive neuroectodermal tumor (PNET) and atypical teratoid/rhabdoid tumor (AT/RT), are the second most prevalent pediatric brain tumor type. AT/RT is highly malignant and is often misdiagnosed as MB or PNET. The distinction of AT/RT from PNET/MB is of clinical significance because the survival rate of patients with AT/RT is substantially lower. The diagnosis of AT/RT relies primarily on morphologic assessment and immunohistochemical (IHC) staining for a few known markers such as the lack of INI1 protein expression. However, in our clinical practice we have observed several AT/RT-like tumors, that fulfilled histopathological and all other biomarker criteria for a diagnosis of AT/RT, yet retained INI1 immunoreactivity. Recent studies have also reported preserved INI1 immunoreactivity among certain diagnosed AT/RTs. It is therefore necessary to re-evaluate INI1(+), AT/RT-like cases.

Method

Sanger sequencing, array CGH and mRNA microarray analyses were performed on PEBT samples to investigate their genomic landscapes.

Results

Patients with AT/RT and those with INI(+) AT/RT-like tumors showed a similar survival rate, and global array CGH analysis and INI1 gene sequencing showed no differential chromosomal aberration markers between INI1(−) AT/RT and INI(+) AT/RT-like cases. We did not misdiagnose MBs or PNETs as AT/RT-like tumors because transcriptome profiling revealed that not only did AT/RT and INI(+) AT/RT-like cases express distinct mRNA and microRNA profiles, their gene expression patterns were different from those of MBs and PNETs. The most similar transcriptome profile to that of AT/RTs was the profile of embryonic stem cells. However; the transcriptome profile of INI1(+) AT/RT-like tumors was more similar to that of somatic neural stem cells, while the profile of MBs was closer to that of fetal brain tissue. Novel biomarkers were identified that can be used to distinguish INI1(−) AT/RTs, INI1(+) AT/RT-like cases and MBs.

Conclusion

Our studies revealed a novel INI1(+) ATRT-like subtype among Taiwanese pediatric patients. New diagnostic biomarkers, as well as new therapeutic tactics, can be developed according to the transcriptome data that were unveiled in this work.

【 授权许可】

   
2015 Ho et al.

【 图 表 】

Fig. 1.

Fig. 2.

Fig. 3.

【 参考文献 】

• [1]Farwell J, Flannery JT: Cancer in relatives of children with central-nervous-system neoplasms. N Engl J Med 1984, 311(12):749-53.
• [2]Mori K, Kurisaka M: Brain tumors in childhood: statistical analysis of cases from the Brain Tumor Registry of Japan. Childs Nerv Syst 1986, 2(5):233-7.
• [3]Biegel JA: Molecular genetics of atypical teratoid/rhabdoid tumor. Neurosurg Focus 2006, 20(1):E11.
• [4]Judkins AR, Mauger J, Ht A, Rorke LB, Biegel JA: Immunohistochemical analysis of hSNF5/INI1 in pediatric CNS neoplasms. Am J Surg Pathol 2004, 28(5):644-50.
• [5]Rorke LB, Packer RJ, Biegel JA: Central nervous system atypical teratoid/rhabdoid tumors of infancy and childhood: definition of an entity. J Neurosurg 1996, 85(1):56-65.
• [6]Buscariollo DL, Park HS, Roberts KB, Yu JB: Survival outcomes in atypical teratoid rhabdoid tumor for patients undergoing radiotherapy in a Surveillance, Epidemiology, and End Results analysis. Cancer 2012, 118(17):4212-9.
• [7]Ho DM, Hsu CY, Wong TT, Ting LT, Chiang H: Atypical teratoid/rhabdoid tumor of the central nervous system: a comparative study with primitive neuroectodermal tumor/medulloblastoma. Acta Neuropathol 2000, 99(5):482-8.
• [8]Burger PC, Yu IT, Tihan T, Friedman HS, Strother DR, Kepner JL, et al.: Atypical teratoid/rhabdoid tumor of the central nervous system: a highly malignant tumor of infancy and childhood frequently mistaken for medulloblastoma: a Pediatric Oncology Group study. Am J Surg Pathol 1998, 22(9):1083-92.
• [9]Haberler C, Laggner U, Slavc I, Czech T, Ambros IM, Ambros PF, et al.: Immunohistochemical analysis of INI1 protein in malignant pediatric CNS tumors: Lack of INI1 in atypical teratoid/rhabdoid tumors and in a fraction of primitive neuroectodermal tumors without rhabdoid phenotype. Am J Surg Pathol 2006, 30(11):1462-8.
• [10]Jackson EM, Sievert AJ, Gai X, Hakonarson H, Judkins AR, Tooke L, et al.: Genomic analysis using high-density single nucleotide polymorphism-based oligonucleotide arrays and multiplex ligation-dependent probe amplification provides a comprehensive analysis of INI1/SMARCB1 in malignant rhabdoid tumors. Clin Cancer Res 2009, 15(6):1923-30.
• [11]Judkins AR: Immunohistochemistry of INI1 expression: a new tool for old challenges in CNS and soft tissue pathology. Adv Anat Pathol 2007, 14(5):335-9.
• [12]Sigauke E, Rakheja D, Maddox DL, Hladik CL, White CL, Timmons CF, et al.: Absence of expression of SMARCB1/INI1 in malignant rhabdoid tumors of the central nervous system, kidneys and soft tissue: an immunohistochemical study with implications for diagnosis. Mod Pathol 2006, 19(5):717-25.
• [13]Bourdeaut F, Freneaux P, Thuille B, Lellouch-Tubiana A, Nicolas A, Couturier J, et al.: hSNF5/INI1-deficient tumours and rhabdoid tumours are convergent but not fully overlapping entities. J Pathol 2007, 211(3):323-30.
• [14]Tsai CY, Wong TT, Lee YH, Chao ME, Lin SC, Liu DJ, et al.: Intact INI1 gene region with paradoxical loss of protein expression in AT/RT: implications for a possible novel mechanism associated with absence of INI1 protein immunoreactivity. Am J Surg Pathol 2012, 36(1):128-33.
• [15]Bhattacharjee M, Hicks J, Langford L, Dauser R, Strother D, Chintagumpala M, et al.: Central nervous system atypical teratoid/rhabdoid tumors of infancy and childhood. Ultrastruct Pathol 1997, 21(4):369-78.
• [16]Huang TS, Hsieh JY, Wu YH, Jen CH, Tsuang YH, Chiou SH, et al.: Functional network reconstruction reveals somatic stemness genetic maps and dedifferentiation-like transcriptome reprogramming induced by GATA2. Stem Cells 2008, 26(5):1186-201.
• [17]Wu YH, Hu TF, Chen YC, Tsai YN, Tsai YH, Cheng CC, Wang HW: The manipulation of microRNA-gene regulatory networks by KSHV induces endothelial cell motility. Blood 2011.
• [18]Yang TP, Chang TY, Lin CH, Hsu MT, Wang HW: ArrayFusion: a web application for multi-dimensional analysis of CGH, SNP and microarray data. Bioinformatics 2006, 22(21):2697-8.
• [19]Hasselblatt M, Gesk S, Oyen F, Rossi S, Viscardi E, Giangaspero F, et al.: Nonsense mutation and inactivation of SMARCA4 (BRG1) in an atypical teratoid/rhabdoid tumor showing retained SMARCB1 (INI1) expression. Am J Surg Pathol 2011, 35(6):933-5.
• [20]Schneppenheim R, Fruhwald MC, Gesk S, Hasselblatt M, Jeibmann A, Kordes U, et al.: Germline nonsense mutation and somatic inactivation of SMARCA4/BRG1 in a family with rhabdoid tumor predisposition syndrome. Am J Hum Genet 2010, 86(2):279-84.
• [21]Kool M, Koster J, Bunt J, Hasselt NE, Lakeman A, van Sluis P, et al.: Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features. PLoS One 2008, 3(8):e3088.
• [22]Ben-Porath I, Thomson MW, Carey VJ, Ge R, Bell GW, Regev A, et al.: An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet 2008, 40(5):499-507.
• [23]Chang SJ, Wang TY, Tsai CY, Hu TF, Chang MD, Wang HW: Increased epithelial stem cell traits in advanced endometrial endometrioid carcinoma. BMC Genomics 2009, 10:613. BioMed Central Full Text
• [24]Hilden JM, Meerbaum S, Burger P, Finlay J, Janss A, Scheithauer BW, et al.: Central nervous system atypical teratoid/rhabdoid tumor: results of therapy in children enrolled in a registry. J Clin Oncol 2004, 22(14):2877-84.
• [25]Tekautz TM, Fuller CE, Blaney S, Fouladi M, Broniscer A, Merchant TE, et al.: Atypical teratoid/rhabdoid tumors (ATRT): improved survival in children 3 years of age and older with radiation therapy and high-dose alkylator-based chemotherapy. J Clin Oncol 2005, 23(7):1491-9.
• [26]Wong DJ, Liu H, Ridky TW, Cassarino D, Segal E, Chang HY: Module map of stem cell genes guides creation of epithelial cancer stem cells. Cell Stem Cell 2008, 2(4):333-44.
• [27]Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, et al.: The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008, 133(4):704-15.
• [28]Morel AP, Lievre M, Thomas C, Hinkal G, Ansieau S, Puisieux A: Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS One 2008, 3(8):e2888.
• [29]Hwang WL, Yang MH, Tsai ML, Lan HY, Su SH, Chang SC, et al.: SNAIL regulates interleukin-8 expression, stem cell-like activity, and tumorigenicity of human colorectal carcinoma cells. Gastroenterology 2011, 141(1):279-91.
• [30]Schuller U, Heine VM, Mao J, Kho AT, Dillon AK, Han YG, et al.: Acquisition of granule neuron precursor identity is a critical determinant of progenitor cell competence to form Shh-induced medulloblastoma. Cancer Cell 2008, 14(2):123-34.
• [31]Picard D, Miller S, Hawkins CE, Bouffet E, Rogers HA, Chan TS, et al.: Markers of survival and metastatic potential in childhood CNS primitive neuro-ectodermal brain tumours: an integrative genomic analysis. Lancet Oncol 2012, 13(8):838-48.
• [32]Bergsland M, Werme M, Malewicz M, Perlmann T, Muhr J: The establishment of neuronal properties is controlled by Sox4 and Sox11. Genes Dev 2006, 20(24):3475-86.
• [33]Fevre-Montange M, Champier J, Szathmari A, Wierinckx A, Mottolese C, Guyotat J, et al.: Microarray analysis reveals differential gene expression patterns in tumors of the pineal region. J Neuropathol Exp Neurol 2006, 65(7):675-84.
• [34]de Bont JM, Kros JM, Passier MM, Reddingius RE, Sillevis Smitt PA, Luider TM, et al.: Differential expression and prognostic significance of SOX genes in pediatric medulloblastoma and ependymoma identified by microarray analysis. Neuro Oncol 2008, 10(5):648-60.
• [35]Lee CJ, Appleby VJ, Orme AT, Chan WI, Scotting PJ: Differential expression of SOX4 and SOX11 in medulloblastoma. J Neurooncol 2002, 57(3):201-14.
• [36]Qiu S, Huang D, Yin D, Li F, Li X, Kung HF, et al.: Suppression of tumorigenicity by microRNA-138 through inhibition of EZH2-CDK4/6-pRb-E2F1 signal loop in glioblastoma multiforme. Biochim Biophys Acta 2013, 1832(10):1697-707.
• [37]Chan XH, Nama S, Gopal F, Rizk P, Ramasamy S, Sundaram G, et al.: Targeting glioma stem cells by functional inhibition of a prosurvival oncomiR-138 in malignant gliomas. Cell reports 2012, 2(3):591-602.
• [38]Rao SA, Arimappamagan A, Pandey P, Santosh V, Hegde AS, Chandramouli BA, et al.: miR-219-5p inhibits receptor tyrosine kinase pathway by targeting EGFR in glioblastoma. PLoS One 2013, 8(5):e63164.
• [39]Dong Q, Cai N, Tao T, Zhang R, Yan W, Li R, et al.: An axis involving SNAI1, microRNA-128 and SP1 modulates glioma progression. PLoS One 2014, 9(6):e98651.